Drug Approval | November 30, 2022
CPHI & PMEC India 2022 showcases array of machinery, ingredients and technology
South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe
South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
The acquired brands are well established and recognized among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness
40,000 visitors and representatives of more than 80 countries set to visit the show
Latest innovations feature vendor-neutral solutions to help reduce clinical complexity and enhance operational efficiency
Approval broadens indication for ENHERTU to earlier use in metastatic breast cancer and requirement for confirmatory phase 3 trial
Joint Drugs Controller (India) Dr PBN Prasad shared his views about working during harsh COVID-19 pandemic days
The receipt of this permission paves way for the launch of Dapagliflozin (Forxiga) tablets of 10 mg in India for the specified additional/expanded indication, subject to the receipt of related statutory approvals
It serves to leverage the strengths of various institutions to coordinate AMR surveillance lab networks
The inspection of the facility resulted in issuance of a Form-483 with eight observations each for the Drug Product facility and API facility at the site
Subscribe To Our Newsletter & Stay Updated
